ClinicalTrials.gg
Status unknownNCT03904823Updated Jul 7, 2022

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

A Phase 2 interventional study of famitinib po and HS-10296 po in EGFR-mutant Non-Small Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-07.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 18 under way, 7 of them phase 3. aumolertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
19th of 29
58 · median 150
Started
2019
with 1 other
Phase 2
14 of 29
7 open now
Registered
3rd of 29
by date
Lead sponsor
1 of 29
Jiangsu HengRui Medicine Co., Ltd.

Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by planned enrollment, is one of 2 that started in 2019, is one of 14 in phase 2, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.

03

Conditions studied

  • EGFR-mutant Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's written obtained prior to any process, sampling, or analysis related to the study.
  • Male or female, no less than 18 years old.
  • Confirmed as NSCLC by histology or cytology.
  • Locally advanced or NSCLC and not suitable for radical surgery or radiotherapy.
  • Have not received EGFR Tyrosine Kinase Inhibitor (TKI) therapy.
  • At least one baseline tumor lesion.
  • Can swallow pills normally.
  • (ECOG) performance status 0\~1 points, expected survival≥12 weeks.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Clinically symptomatic central nervous system .
  • Ascites, pleural effusion or pericardial effusion with clinical symptoms.
  • Other malignant tumors in the past 5 years or at the same time.
  • High blood pressure which are not well controlled.
  • Heart disease that are not well controlled.
  • Coagulation dysfunction, bleeding tendency or receiving thrombolysis or anticoagulant therapy.
  • History of bleeding.
  • Known hereditary or acquired bleeding and thrombophilia.
  • Any serious or uncontrolled ocular lesion.
  • Interstitial lung disease or non-infectious pneumonia treated with .
  • Congenital or acquired immunodeficiency.
  • Other factors that may affect the results of the study or cause the study to be terminated midway.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    famitinib, HS-10296

    Drug: famitinib po · Drug: HS-10296 po

Interventions

  • Drugfamitinib po

    Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.

  • Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Secondary outcomes

  1. Depth of Response (DepOR)

    Percentage of total target lesion diameter reduced from baseline when at best overall response

    Time frame: From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  2. Duration of Response (DOR)

    Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: From the first partial response or complete response until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  3. Disease Control Rate (DCR)

    Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  4. Clinical Benefit Ratio (CBR)

    Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: From the start of treatment to 6 months

  5. 12-month-PFS

    12-month-progression free survival rate

    Time frame: From the start of treatment to 12 months

  6. Progression-Free-Survival (PFS)

    Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: up to 2 years

  7. Number of Participants with Clinically significant toxicity

    Number of Participants with Clinically significant toxicity per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

    Time frame: First cycle (21 days)

  8. Rate of Adverse Events and Serious Adverse Events

    Rate of Adverse Events and Serious Adverse Events per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

    Time frame: From the first drug administration to within 30 days after the last dose

07

Study locations

1 of 1 sites recruiting
  • Tongji University, Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200433, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Dec 2022, 44 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 44 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2019
First posted
Apr 5, 2019
StartActual
Apr 25, 2019
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
Jul 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03904823
Responsible party
Sponsor
First posted
Apr 5, 2019
Start date
Apr 25, 2019
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Jul 7, 2022

Study contacts

Quanren Wang, PhD
Contact
wangquanren@hrglobe.cn
+86 18036618570
Weixia Li, Master
Contact
liweixia@hrglobe.cn
+86 15005136260
Caicun Zhou, PhD
principal investigator · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion